DUBLIN--(BUSINESS WIRE)--The "Global Immune Thrombocytopenia Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
Market Overview
Expected approvals for late-stage pipeline molecules
The market is witnessing accelerated growth in the number of molecules in the pipeline for the treatment of immune thrombocytopenia. At present, there are over 5 therapeutics to treat immune thrombocytopenia. These drugs are in the late stages of development and are slated to receive marketing approvals during the forecast period.
Availability of substitutes
The side effects associated with the available drugs for the treatment of immune thrombocytopenia are forcing healthcare practitioners to adopt alternative treatment options such as platelet transfusion and surgery. These treatment options have higher efficacies when compared to the available drugs. This is expected to pose a challenge to the growth of the global immune thrombocytopenia market size.
Competitive Landscape
The market appears to be fragmented with several players occupying the market share. Companies such as Amgen Inc. and CSL Ltd. Have intensified the competition. Factors such as the high prevalence of associated risk factors for immune thrombocytopenia and the expected approvals of late-stage pipeline molecules will provide significant growth opportunities for immune thrombocytopenia drug manufacturers. Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc. are some of the major companies covered in this report.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- TPO-RAs - Market size and forecast 2018-2023
- Corticosteroids - Market size and forecast 2018-2023
- IVIGs - Market size and forecast 2018-2023
- Other drugs - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
- Special regulatory designations
- Increasing number of awareness programs
- Development of biosimilars
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
- Rigel Pharmaceuticals Inc.
PART 14: APPENDIX
- Research methodology
- List of abbreviations
-
Definition of market positioning of vendors
For more information about this report visit https://www.researchandmarkets.com/r/tstof2